BIMZELX (bimekizumab-bkzx) is a humanized monoclonal antibody indicated for the treatment of several chronic inflammatory conditions in adult patients. It is approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as those with active psoriatic arthritis. Additionally, the therapy is indicated for the treatment of active non-radiographic axial spondyloarthritis, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa.
How BIMZELX Works
Bimekizumab-bkzx is an immunoglobulin IgG1/κ monoclonal antibody that selectively binds to the IL-17A, IL-17F, and IL-17-AF cytokines. By binding to these targets, the drug inhibits their interaction with the IL-17 receptor complex. This action prevents the release of proinflammatory cytokines and chemokines that are involved in normal and pathological inflammatory and immune responses.
Details
- Status
- Prescription
- First Approved
- 2023-10-17
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
BIMZELX Approval History
What BIMZELX Treats
5 indicationsBIMZELX is approved for 5 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Plaque Psoriasis
- Psoriatic Arthritis
- Non-Radiographic Axial Spondyloarthritis
- Ankylosing Spondylitis
- Hidradenitis Suppurativa
BIMZELX Target & Pathway
ProTarget
A pro-inflammatory cytokine produced by Th17 cells that plays a key role in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Blocking IL-17 reduces the inflammatory cascade that causes skin plaques and joint inflammation.
BIMZELX Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in BIMZELX's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications BIMZELX treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to BIMZELX
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
UCB INC's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BIMZELX FDA Label Details
Indications & Usage
FDA Label (PDF)BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. Adults with active psoriatic arthritis (PsA) . Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. Adults with active ankylosing spondylitis ( AS ). Adults with moderate to severe hidradenitis suppurativa (HS) . 1.1 Plaque Psoriasis BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for ...
Track BIMZELX with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.